INT2106

INT2106 is an investigational in vivo chimeric antigen receptor (CAR) gene therapy developed by Interius BioTherapeutics. It utilizes engineered lentiviral vectors to deliver a CAR gene directly to T and NK cells within the patient’s body, resulting in the generation of CAR T and CAR NK cells that specifically target and eliminate CD19-expressing B cells. This approach aims to induce immune reset by depleting autoreactive B cells responsible for producing pathogenic autoantibodies in various autoimmune diseases. Unlike traditional ex vivo CAR therapies, INT2106 eliminates the need for cell extraction and manipulation outside the body. Preclinical studies have demonstrated complete depletion of human B cells in humanized mouse models as well as supportive safety data from GLP toxicology studies[1][2][3].